380 related articles for article (PubMed ID: 15252141)
1. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
Deeb D; Jiang H; Gao X; Hafner MS; Wong H; Divine G; Chapman RA; Dulchavsky SA; Gautam SC
Mol Cancer Ther; 2004 Jul; 3(7):803-12. PubMed ID: 15252141
[TBL] [Abstract][Full Text] [Related]
2. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis.
Deeb DD; Jiang H; Gao X; Divine G; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2005; 5(2):81-91. PubMed ID: 16471035
[TBL] [Abstract][Full Text] [Related]
5. Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis.
Kim KW; Kim BJ; Chung CW; Jo DG; Kim IK; Song YH; Kwon YK; Woo HN; Jung YK
J Cell Biochem; 2002; 85(2):334-45. PubMed ID: 11948689
[TBL] [Abstract][Full Text] [Related]
6. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells.
Deeb D; Xu YX; Jiang H; Gao X; Janakiraman N; Chapman RA; Gautam SC
Mol Cancer Ther; 2003 Jan; 2(1):95-103. PubMed ID: 12533677
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.
Liao X; Zhang L; Thrasher JB; Du J; Li B
Mol Cancer Ther; 2003 Nov; 2(11):1215-22. PubMed ID: 14617795
[TBL] [Abstract][Full Text] [Related]
8. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes.
Shukla S; Gupta S
Clin Cancer Res; 2004 May; 10(9):3169-78. PubMed ID: 15131058
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
Sanlioglu AD; Koksal IT; Karacay B; Baykara M; Luleci G; Sanlioglu S
Cancer Gene Ther; 2006 Jan; 13(1):21-31. PubMed ID: 16052230
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression.
Kim KM; Song JJ; An JY; Kwon YT; Lee YJ
J Biol Chem; 2005 Dec; 280(49):41047-56. PubMed ID: 16199534
[TBL] [Abstract][Full Text] [Related]
11. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand.
Qin JZ; Bacon P; Chaturvedi V; Nickoloff BJ
J Invest Dermatol; 2001 Oct; 117(4):898-907. PubMed ID: 11676830
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin.
Ma Y; Lakshmikanthan V; Lewis RW; Kumar MV
Mol Cancer Ther; 2006 Jan; 5(1):170-8. PubMed ID: 16432176
[TBL] [Abstract][Full Text] [Related]
13. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Chawla-Sarkar M; Bauer JA; Lupica JA; Morrison BH; Tang Z; Oates RK; Almasan A; DiDonato JA; Borden EC; Lindner DJ
J Biol Chem; 2003 Oct; 278(41):39461-9. PubMed ID: 12881518
[TBL] [Abstract][Full Text] [Related]
14. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells.
Franco AV; Zhang XD; Van Berkel E; Sanders JE; Zhang XY; Thomas WD; Nguyen T; Hersey P
J Immunol; 2001 May; 166(9):5337-45. PubMed ID: 11313369
[TBL] [Abstract][Full Text] [Related]
15. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation.
Lee KY; Park JS; Jee YK; Rosen GD
Exp Mol Med; 2002 Dec; 34(6):462-8. PubMed ID: 12526088
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Secchiero P; Milani D; Gonelli A; Melloni E; Campioni D; Gibellini D; Capitani S; Zauli G
J Leukoc Biol; 2003 Aug; 74(2):223-32. PubMed ID: 12885939
[TBL] [Abstract][Full Text] [Related]
17. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.
Ravi R; Bedi GC; Engstrom LW; Zeng Q; Mookerjee B; Gélinas C; Fuchs EJ; Bedi A
Nat Cell Biol; 2001 Apr; 3(4):409-16. PubMed ID: 11283615
[TBL] [Abstract][Full Text] [Related]
18. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis.
Kim HS; Chang I; Kim JY; Choi KH; Lee MS
Cancer Res; 2005 Jul; 65(14):6111-9. PubMed ID: 16024612
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor".
Muenchen HJ; Lin DL; Walsh MA; Keller ET; Pienta KJ
Clin Cancer Res; 2000 May; 6(5):1969-77. PubMed ID: 10815922
[TBL] [Abstract][Full Text] [Related]
20. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
